O	0	9	Adherence
O	10	12	to
O	13	16	the
B-intervention	17	24	Western
I-intervention	24	25	,
I-intervention	26	33	Prudent
I-intervention	34	37	and
I-intervention	38	51	Mediterranean
I-intervention	52	59	dietary
O	60	68	patterns
O	69	72	and
O	73	79	breast
O	80	86	cancer
O	87	91	risk
O	91	92	:
O	93	96	MCC
O	96	97	-
O	97	102	Spain
O	103	108	study
O	108	109	.

O	110	112	To
O	113	123	externally
O	124	132	validate
O	133	136	the
O	137	147	previously
O	148	158	identified
O	159	165	effect
O	166	168	on
O	169	175	breast
O	176	182	cancer
O	183	187	risk
O	188	190	of
O	191	194	the
O	195	202	Western
O	202	203	,
O	204	211	Prudent
O	212	215	and
O	216	229	Mediterranean
O	230	237	dietary
O	238	246	patterns
O	246	247	.

O	248	251	MCC
O	251	252	-
O	252	257	Spain
O	258	260	is
O	261	262	a
O	263	272	multicase
O	272	273	-
O	273	280	control
O	281	286	study
O	287	291	that
O	292	301	collected
O	302	317	epidemiological
O	318	329	information
O	330	332	on
B-intervention-participants	333	337	1181
O	338	346	incident
O	347	352	cases
O	353	355	of
O	356	362	female
O	363	369	breast
O	370	376	cancer
O	377	380	and
B-control-participants	381	385	1682
O	386	393	healthy
B-control	394	402	controls
O	403	407	from
O	408	410	10
B-location	411	418	Spanish
I-location	419	428	provinces
O	428	429	.

O	430	435	Three
O	436	443	dietary
O	444	452	patterns
O	453	460	derived
O	461	463	in
O	464	471	another
O	472	479	Spanish
O	480	484	case
O	484	485	-
O	485	492	control
O	493	498	study
O	499	503	were
O	504	512	analysed
O	513	515	in
O	516	519	the
O	520	523	MCC
O	523	524	-
O	524	529	Spain
O	530	535	study
O	535	536	.

O	537	542	These
O	543	551	patterns
O	552	556	were
O	557	563	termed
O	564	571	Western
O	572	573	(
O	573	577	high
O	578	585	intakes
O	586	588	of
O	589	594	fatty
O	595	598	and
O	599	605	sugary
O	606	614	products
O	615	618	and
O	619	622	red
O	623	626	and
O	627	636	processed
O	637	641	meat
O	641	642	)
O	642	643	,
O	644	651	Prudent
O	652	653	(
O	653	657	high
O	658	665	intakes
O	666	668	of
O	669	672	low
O	672	673	-
O	673	676	fat
O	677	682	dairy
O	683	691	products
O	691	692	,
O	693	703	vegetables
O	703	704	,
O	705	711	fruits
O	711	712	,
O	713	718	whole
O	719	725	grains
O	726	729	and
O	730	736	juices
O	736	737	)
O	738	741	and
O	742	755	Mediterranean
O	756	757	(
O	757	761	high
O	762	768	intake
O	769	771	of
O	772	776	fish
O	776	777	,
O	778	788	vegetables
O	788	789	,
O	790	797	legumes
O	797	798	,
O	799	805	boiled
O	806	814	potatoes
O	814	815	,
O	816	822	fruits
O	822	823	,
O	824	830	olives
O	830	831	,
O	832	835	and
O	836	845	vegetable
O	846	849	oil
O	849	850	,
O	851	854	and
O	855	856	a
O	857	860	low
O	861	867	intake
O	868	870	of
O	871	877	juices
O	877	878	)
O	878	879	.

O	880	885	Their
O	886	897	association
O	898	902	with
O	903	909	breast
O	910	916	cancer
O	917	920	was
O	921	929	assessed
O	930	935	using
O	936	944	logistic
O	945	955	regression
O	956	962	models
O	963	967	with
O	968	974	random
O	975	983	province
O	983	984	-
O	984	992	specific
O	993	1003	intercepts
O	1004	1015	considering
O	1016	1018	an
O	1019	1030	interaction
O	1031	1035	with
O	1036	1046	menopausal
O	1047	1053	status
O	1053	1054	.

O	1055	1059	Risk
O	1060	1069	according
O	1070	1072	to
O	1073	1079	tumour
O	1080	1088	subtypes
O	1089	1090	-
O	1091	1096	based
O	1097	1099	on
O	1100	1109	oestrogen
O	1110	1111	(
O	1111	1113	ER
O	1113	1114	)
O	1114	1115	,
O	1116	1128	progesterone
O	1129	1130	(
O	1130	1132	PR
O	1132	1133	)
O	1134	1137	and
O	1138	1143	human
O	1144	1153	epidermal
O	1154	1160	growth
O	1161	1167	factor
O	1168	1169	2
O	1170	1171	(
O	1171	1175	HER2
O	1175	1176	)
O	1177	1186	receptors
O	1187	1188	(
O	1188	1190	ER
O	1190	1191	+
O	1191	1192	/
O	1192	1194	PR
O	1194	1195	+
O	1196	1197	&
O	1198	1202	HER2
O	1202	1203	-
O	1203	1204	;
O	1205	1209	HER2
O	1209	1210	+
O	1210	1211	;
O	1212	1214	ER
O	1214	1215	-
O	1215	1216	/
O	1216	1218	PR
O	1218	1219	-
O	1220	1221	&
O	1222	1226	HER2
O	1226	1227	-
O	1227	1228	)
O	1229	1230	-
O	1231	1234	was
O	1235	1244	evaluated
O	1245	1249	with
O	1250	1261	multinomial
O	1262	1272	regression
O	1273	1279	models
O	1279	1280	.

O	1281	1287	Breast
O	1288	1294	cancer
O	1295	1298	and
O	1299	1311	histological
O	1312	1319	subtype
O	1319	1320	.

O	1321	1324	Our
O	1325	1332	results
O	1333	1340	confirm
O	1341	1345	most
O	1346	1348	of
O	1349	1352	the
O	1353	1365	associations
O	1366	1371	found
O	1372	1374	in
O	1375	1378	the
O	1379	1387	previous
O	1388	1392	case
O	1392	1393	-
O	1393	1400	control
O	1401	1406	study
O	1406	1407	.

O	1408	1409	A
O	1410	1414	high
O	1415	1424	adherence
O	1425	1427	to
O	1428	1431	the
O	1432	1439	Western
O	1440	1447	dietary
O	1448	1455	pattern
O	1456	1461	seems
O	1462	1464	to
O	1465	1473	increase
B-outcome	1474	1480	breast
I-outcome	1481	1487	cancer
I-outcome	1488	1492	risk
I-outcome	1493	1495	in
I-outcome	1496	1500	both
I-outcome	1501	1514	premenopausal
I-outcome	1515	1520	women
O	1521	1522	(
O	1522	1529	OR4thvs
O	1529	1530	.
O	1530	1541	1stquartile
O	1542	1543	(
O	1543	1545	95
O	1545	1546	%
O	1547	1549	CI
O	1549	1550	)
O	1550	1551	:
O	1551	1552	1
O	1552	1553	.
O	1553	1555	68
O	1556	1557	(
O	1557	1558	1
O	1558	1559	.
O	1559	1561	02
O	1561	1562	;
O	1562	1563	2
O	1563	1564	.
O	1564	1566	79
O	1566	1567	)
O	1567	1568	;
O	1569	1574	OR1SD
O	1574	1575	-
O	1575	1583	increase
O	1584	1585	(
O	1585	1587	95
O	1587	1588	%
O	1589	1591	CI
O	1591	1592	)
O	1592	1593	:
O	1593	1594	1
O	1594	1595	.
O	1595	1597	19
O	1598	1599	(
O	1599	1600	1
O	1600	1601	.
O	1601	1603	02
O	1603	1604	;
O	1604	1605	1
O	1605	1606	.
O	1606	1608	40
O	1608	1609	)
O	1609	1610	)
B-outcome	1611	1614	and
I-outcome	1615	1629	postmenopausal
I-outcome	1630	1635	women
O	1636	1637	(
O	1637	1644	OR4thvs
O	1644	1645	.
O	1645	1656	1stquartile
O	1656	1657	(
O	1657	1659	95
O	1659	1660	%
O	1661	1663	CI
O	1663	1664	)
O	1664	1665	:
O	1665	1666	1
O	1666	1667	.
O	1667	1669	48
O	1669	1670	(
O	1670	1671	1
O	1671	1672	.
O	1672	1674	07
O	1674	1675	;
O	1675	1676	2
O	1676	1677	.
O	1677	1679	05
O	1679	1680	)
O	1680	1681	;
O	1682	1687	OR1SD
O	1687	1688	-
O	1688	1696	increase
O	1696	1697	(
O	1697	1699	95
O	1699	1700	%
O	1701	1703	CI
O	1703	1704	)
O	1704	1705	:
O	1706	1707	1
O	1707	1708	.
O	1708	1710	14
O	1711	1712	(
O	1712	1713	1
O	1713	1714	.
O	1714	1716	01
O	1716	1717	;
O	1717	1718	1
O	1718	1719	.
O	1719	1721	29
O	1721	1722	)
O	1722	1723	)
O	1723	1724	.

O	1725	1730	While
O	1731	1735	high
O	1736	1745	adherence
O	1746	1748	to
O	1749	1752	the
O	1753	1760	Prudent
O	1761	1768	pattern
O	1769	1772	did
O	1773	1776	not
O	1777	1781	show
O	1782	1785	any
B-outcome	1786	1792	effect
I-outcome	1793	1795	on
I-outcome	1796	1802	breast
I-outcome	1803	1809	cancer
O	1809	1810	,
O	1811	1814	the
O	1815	1828	Mediterranean
O	1829	1836	dietary
O	1837	1844	pattern
O	1845	1851	seemed
O	1852	1854	to
O	1855	1857	be
B-outcome	1858	1868	protective
O	1868	1869	,
O	1870	1873	but
O	1874	1878	only
O	1879	1884	among
O	1885	1899	postmenopausal
O	1900	1905	women
O	1906	1907	(
O	1907	1914	OR4thvs
O	1914	1915	.
O	1915	1926	1stquartile
O	1927	1928	(
O	1928	1930	95
O	1930	1931	%
O	1932	1934	CI
O	1934	1935	)
O	1935	1936	:
O	1937	1938	0
O	1938	1939	.
O	1939	1941	72
O	1942	1943	(
O	1943	1945	95
O	1945	1946	%
O	1947	1949	CI
O	1950	1951	0
O	1951	1952	.
O	1952	1954	53
O	1954	1955	;
O	1955	1956	0
O	1956	1957	.
O	1957	1959	98
O	1959	1960	)
O	1960	1961	;
O	1962	1963	p
O	1963	1964	-
O	1964	1967	int
O	1967	1968	=
O	1968	1969	0
O	1969	1970	.
O	1970	1973	075
O	1973	1974	)
O	1974	1975	.

O	1976	1981	There
O	1982	1986	were
O	1987	1989	no
O	1990	2001	significant
O	2002	2013	differences
O	2014	2016	by
O	2017	2023	tumour
O	2024	2031	subtype
O	2031	2032	.

O	2033	2040	Dietary
O	2041	2056	recommendations
O	2057	2062	based
O	2063	2065	on
O	2066	2067	a
O	2068	2077	departure
O	2078	2082	from
O	2083	2086	the
O	2087	2094	Western
O	2095	2102	dietary
O	2103	2110	pattern
O	2111	2113	in
O	2114	2120	favour
O	2121	2123	of
O	2124	2127	the
O	2128	2141	Mediterranean
O	2142	2146	diet
O	2147	2152	could
O	2153	2159	reduce
O	2160	2166	breast
O	2167	2173	cancer
O	2174	2178	risk
O	2179	2181	in
O	2182	2185	the
O	2186	2193	general
O	2194	2204	population
O	2204	2205	.
